Ovarian Cancer Clinical Trials

Showing 1161-1169 of 1,169 trials

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

NCT00190697

Patients who were previously enrolled on the LY353381 arm of any LY353381 oncology trial could enroll in this "roll-over" study if they had exhibited clinical benefit from treatment and wished to continue on treatment. Patients were monitored for safety.

Breast CancerEndometrial CancerOvarian Cancer

Eli Lilly and Company70 participantsStarted Jan 2001

Houston, Texas, United States

UNKNOWN

MRI in Staging Ovarian Cancer Using MRI Contrast Agent

NCT00463996

Can MRI be used to stage ovarian cancer?

Ovarian Cancer

University of Aarhus50 participantsStarted Apr 2007

TERMINATEDNA

Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.

NCT00287482

This is a pilot feasibility study being performed in women completing front-line treatment for breast or ovarian cancer. It is being done to evaluate whether or not an herbal combination known as Essiac (ESIAK) can improve the overall quality of life in these women as they transition from active treatment to follow-up, also known as the quality of life in transition. This information will be used to design a larger randomized trial.

Ovarian CancerBreast Cancer

Women and Infants Hospital of Rhode Island20 participantsStarted Oct 2005

Providence, Rhode Island, United States

UNKNOWN

Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas

NCT00419627

The purpose of this study is to evaluate the presence of proteins in solid tumors which may lead to an immune response

Colorectal NeoplasmsStomach NeoplasmsPancreatic Neoplasms+2 more

Hillel Yaffe Medical Center160 participantsStarted Feb 2007

Hadera, Israel

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

MRI in Staging Ovarian Cancer Using MRI Contrast Agent

Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.

Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas

Related Searches

The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients

Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer

Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients

Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response

Mesothelin as a New Tumor Marker for Ovarian Cancer